Social media

Attending #OCTSoutheast 10-11 March? Stop by booth \#37 to learn how we support biotechs with flexible clinical development, operational expertise and data‑driven decision‑making. https://lnkd.in/ehPmQF\_H

From feasibility to activation, study start-up delays can erode momentum and inflate costs. ICON’s Brian Mallon offers perspective and outlines practical fixes, including AI-driven contracting, early site engagement, and...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

ICON has participated in 193 neurodegenerative and neuromuscular studies, enrolling 18,200+ patients at 4,800+ sites globally. Meet our experts at #ADPD2026, booth \#29 to learn how we can support your neurodegeneration ...

The type of immunosuppressive treatment a patient with a rare autoimmune condition receives may impact how they respond to vaccines. Read our new article to explore this and other factors that can help determine the best...

Only one day until #OCT Southeast begins. ICON will be on site 10–11 March, ready to connect with biotechs looking to strengthen clinical delivery. Visit Booth \#37 to meet our team and discuss how our expertise supports...

Meet the ICON team at Medidata NEXT New York. Our specialists will be available throughout the event to discuss how ICON is supporting sponsors to improve study build quality, streamline delivery and adopt technology wit...

A multi phase ICON supported study details the leading symptoms in advanced/metastatic HCC including fatigue, weight loss, weakness, appetite loss, and sleep disturbance. Findings show wide ranging effects on daily fun...

ICON is proud to be recognised among the top global companies in the world for female employees. As of 31 December 2024, women make up 70% of our workforce and hold 60% of director-level and above roles—a powerful refle...

Join Steve Hunt at Medidata NEXT New York for a roundtable discussion on real world lessons from early adopters of Medidata Designer. Steve will share what effective adoption looks like in practice, where ICON teams are ...

The oncology R&D landscape is rapidly evolving, driven by multi‑modality therapeutics, precision‑designed studies, and the growing measurable impact of AI on discovery and development. These shifts are reshaping how spon...

Last week, our teams across ICON came together to recognise Rare Disease Day and raise awareness for the millions of people and families living with rare conditions. Colleagues took part in activities including creating...